Startups
Novaremed AG is a clinical-stage Swiss biopharmaceutical company, HQ in Basel, Switzerland, with a subsidiary in Israel. Novaremed is developing an orally active, first-in-class, small molecule (NRD.E1), with a novel mechanism of action, to treat Diabetic Neuropathic Pain.
Overview
Employees
11-50
Total raised
$55.37M
Founded date
2008
Funding Rounds 3
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Sep 21, 2020 | Funding round | $2.73M | |
| Sep 2, 2019 | Funding round | $2.64M |
Mentions in press and media 17
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 25, 2022 | Novaremed receives USD 130 million in exclusive license agreement | |
| Dec 29, 2021 | Novaremed’s lead molecule enters Phase2b trials | |
| Sep 14, 2021 | Novaremed acquires Basel-based Metys Pharmaceuticals | Novaremed, a privately-held clinical-stage biopharmaceutical company, announces the acquisition of Metys Pharmaceuticals AG (Metys), including all of its development programs, in an all-share transaction. The acquisition broadens Novaremed’... |
| Feb 4, 2021 | Novaremed Secures US$50M | Novaremed AG, a Basel, Switzerland-based clinical-stage biopharmaceutical company, announced, signed an agreement with GEM Global Yield LLC SCS (GEM), a Luxembourg-based private, alternative investment group for a US $50m capital commitment... |
| Jan 29, 2021 | Novaremed Secures US $50 Million | Under the agreement, GEM commits to provide Novaremed with a share subscription facility of up to US $50 million for a 36-month term following the public listing of the company’s shares. Novaremed will control the timing and maximum amount ... |
| Jan 29, 2021 | Novaremed Secures US $50 Million | |
| Jan 28, 2021 | Novaremed Secures US $50 Million Capital Commitment from Global Emerging Markets | BASEL, Switzerland–(BUSINESS WIRE)–Jan 28, 2021– Novaremed AG (Novaremed), a clinical-stage Swiss biopharmaceutical company, announced today that it has signed an agreement with GEM Global Yield LLC SCS (GEM), a Luxembourg-based private, al... |
| Sep 21, 2020 | Novaremed raises CHF2.5 million and prepares Phase2b clinical study | The round brings the total financing raised by the company, since its inception, to CHF23.5 million. “The oversubscription of the new financing is a strong endorsement by our shareholders of the major milestone achieved by the company by se... |
| Sep 21, 2020 | Novaremed raises CHF2.5 million and prepares Phase2b clinical study |
Show more
Reviews 0
FAQ about Novaremed
When was Novaremed founded?
Novaremed was founded in 2008.
How much funding has Novaremed raised?
Novaremed has raised $55.37M in total across 3 funding rounds.
What funding rounds has Novaremed raised?
Parsers VC lists 3 funding rounds of Novaremed, among them a funding round of $2.73M on Sep 21, 2020 and a funding round of $2.64M on Sep 2, 2019.
What has the press written about Novaremed?
Parsers VC has collected 17 articles mentioning Novaremed, among them “Novaremed receives USD 130 million in exclusive license agreement” (Jul 25, 2022) and “Novaremed’s lead molecule enters Phase2b trials” (Dec 29, 2021).
Is Novaremed still active?
Yes, Novaremed is active; its latest activity on Parsers VC dates from May 9, 2025.